Global Blood Therapeutics Inc
NASDAQ:GBT
Global Blood Therapeutics Inc
Operating Income
Global Blood Therapeutics Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Global Blood Therapeutics Inc
NASDAQ:GBT
|
Operating Income
-$299.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$7.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
See Also
What is Global Blood Therapeutics Inc's Operating Income?
Operating Income
-299.2m
USD
Based on the financial report for Jun 30, 2022, Global Blood Therapeutics Inc's Operating Income amounts to -299.2m USD.
What is Global Blood Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-25%
Over the last year, the Operating Income growth was -17%. The average annual Operating Income growth rates for Global Blood Therapeutics Inc have been -12% over the past three years , -25% over the past five years .